In particular, the down-regulation of ADNP may concur with dopaminergic neurodegeneration in Parkinson’s Disease [45], and the ADNP plasma/serum and lymphocyte mRNA levels were correlated to clinical stage and Alzheimer’s disease (AD) biomarkers [46]. This evidence concerns the gene ADNP and early-onset autosomal dominant Alzheimer disease.